Value of surveillance studies for patients (pts) with stage I-II diffuse large B-cell lymphoma (DLBCL) in the rituximab (R) era.
Susan M. Hiniker
No relevant relationships to disclose
Erqi L. Pollom
No relevant relationships to disclose
Michael S. Khodadoust
No relevant relationships to disclose
Margaret M. Kozak
No relevant relationships to disclose
Ranjana H. Advani
No relevant relationships to disclose
Richard T. Hoppe
No relevant relationships to disclose